fluphenazine decanoate
Long-acting injectable antipsychotic • Brands: PROLIXIN DECANOATE
Last reviewed: 2025-12-30
General information
- Class: Long-acting injectable antipsychotic
- Common US brands: PROLIXIN DECANOATE
- Long-acting injectable formulation available.
- Therapeutic drug monitoring not routinely recommended.
- Last reviewed: 2025-12-30
Dosing & forms
- Forms/strengths: —
- Frequency: —
- Food: —
- Typical range: —
Mechanism (brief)
Long-acting injectable formulation of fluphenazine (high-potency phenothiazine D2 antagonist) used for schizophrenia maintenance when depot dosing supports adherence.
Metabolism & Half‑life
- Metabolism: CYP2D6
- Half‑life: —
Therapeutic Drug Monitoring (TDM)
Recommended: No
Long‑acting injectable (LAI)
Monitoring highlights
- —
Sources
- Fluphenazine decanoate prescribing information — DailyMed (2024)
- The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia — American Psychiatric Association (2020)
- Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis — The Lancet (2013)
- AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsycharmacology — Pharmacopsychiatry (2018)
- Triple advantages of injectable long acting second generation antipsychotics: relapse prevention, neuroprotection, and lower mortality — Schizophrenia Research (2018)